Загрузка видео...

Не удалось загрузить видео

На главную

STUDY FINDS HIGH-DOSE IV VITAMIN C LINKED TO COMPLETE REMISSIONS IN MULTIPLE ADVANCED CANCER PATIENTS WHO DECLINED CHEMOTHERAPY METASTATIC KIDNEY CANCER: “Cannonball” lung tumors disappeared; complete remission lasted >4 years. MUSCLE-INVASIVE BLADDER CANCER: No recurrence or metastasis 9 years later. STAGE III AGGRESSIVE LYMPHOMA: No clinical signs of cancer...

181,064 просмотров • 3 дней назад •via X (Twitter)

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Megyn Kelly sat down with Dr. Patrick Soon-Shiong to discuss his revolutionary cancer protocol—a treatment that has already extended lives by years for patients with terminal diagnoses, including the late Senator Harry Reid. The Science Behind the Breakthrough Dr. Soon-Shiong’s approach challenges conventional cancer treatments like chemotherapy and radiation, which destroy the immune system’s natural killer (NK) cells and T-cells—critical for fighting cancer. His BioStripe treatment works by rebuilding the immune system, even in patients who have exhausted all other options. Real Patients, Miraculous Results Merkel cell carcinoma (5th-line treatment): Complete remission—patient lived 6+ years and didn’t die from cancer. Bladder cancer: Patients still alive 10-11 years later. Triple-negative breast cancer: Multiple complete remissions. Metastatic pancreatic cancer: One patient disease-free after 5 years, now 6+ years and counting. FDA Roadblocks & Lost Time Despite undeniable success, Dr. Soon-Shiong faced years of resistance from regulators. In 2015, he proposed testing his method before chemo/radiation—but the FDA insisted on starting with end-stage patients. After 700,000 pages of submissions, approval finally came in late 2024. The Future: Beyond Cancer This treatment isn’t just for cancer—it’s showing promise against sepsis and severe infections. One recent case: A Valley Fever patient on a ventilator, given last rites—fully recovered after treatment. The Urgent Question Why is bureaucracy slowing down a therapy that could save millions? With pancreatic cancer, glioblastoma, and lung cancer patients still dying every day, how many more lives could have been saved if this had been fast-tracked?

Camus

615,893 просмотров • 1 год назад

When I caught Covid, my friends rushed doses of Ivermectin to me — kicked Covid in 24 hours. Here’s a cancer surgeon revealing her discoveries about the impact of Ivermectin on CANCER… 9 min. must see: Also — Compelling Evidence for Ivermectin in Treating Covid: · Front Line COVID-19 Critical Care Alliance Review — This review, which summarized findings from 27 studies, concluded that ivermectin demonstrates a strong signal of therapeutic efficacy against COVID-19. This includes both prevention and treatment aspects. · Meta-Analysis on Ivermectin — A meta-analysis covering 96 studies and over 135,000 patients suggests that ivermectin has shown effectiveness in combating COVID-19. This analysis points towards ivermectin's role in reducing severity and improving health outcomes. · Antiviral Effect Study — A study aimed at assessing the antiviral effect of high-dose ivermectin found it to have an impact on viral load, suggesting its potential in reducing the severity of the disease by decreasing the viral replication. Evidence for Ivermectin in Treating Cancer as summarized by Dr. William Makis, Radiologist, Oncologist, Cancer Researcher. NEW ARTICLE: IVERMECTIN and Protocols for CANCER Ivermectin has a dozen anti-cancer mechanisms but they can be summarized into two main ones: 1. Inhibits cancer proliferation signaling pathways (Akt, mTOR, Wnt) 2. Inhibits Cancer Stem Cells IVERMECTIN will act against regular CANCER as well as Pfizer and Moderna COVID-19 mRNA Vaccine Induced TURBO CANCER (which is highly resistant to chemo) Here are recent studies on IVERMECTIN use in certain types of cancer: BLADDER CANCER - (2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage LUNG CANCER - (2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells GLIOMA - (2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma MULTIPLE MYELOMA - (2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma OVARIAN CANCER - (2023 Jawad et al) - Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells PROSTATE CANCER - (2022 Lu et al) - Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer COLON CANCER - (2022, Alghamdi et al) - Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats PANCREATIC CANCER - (2022 Lee et al) - Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction MELANOMA - (2022 Zhang et al) - Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis IVERMECTIN has proven anti-cancer activity against some 20 cancer types, although these are pre-clinical studies. We will never see clinical studies because Ivermectin is off patent and cheap. Merck, which used to have a patent on Ivermectin, has partnered with Moderna on mRNA Cancer Vaccines. IVERMECTIN is so safe, that in much of the civilized world, it is available over the counter, no prescription needed. Ivermectin is annually taken by close to 250 million people.

Bobby

160,046 просмотров • 1 год назад

A New Dawn in the Cancer War: Pioneering "BioShield" Technology Achieves Long-Term Remission Where Others Failed A stunning revelation from Dr. Patrick Soon-Shiong on the dawn of a new medical era. He details a breakthrough he calls "BioShield," a technology designed to prevent cancer by fundamentally educating the body's own immune system. Forget conventional vaccines. This isn't about antibodies. This is about creating a living, intelligent defense system within you. Here’s the concept: "BioShield" educates your T-cells to become elite "memory" cells. They then hide in your bone marrow, lying in wait. When a cancerous cell appears, they emerge to seek and destroy it—stopping cancer before it can ever gain a foothold. This isn't science fiction. It's peer-reviewed, published science with the National Cancer Institute (NCI). And the results are nothing short of remarkable: ➡️ Bladder Cancer: Patients who failed all other treatments and faced radical bladder removal have achieved complete remission for nine years after a simple injection. No surgery. Just a functional cure. ➡️ Pancreatic Cancer: A disease with a grim prognosis, now seeing patients disease-free for five years. The late Senator Harry Reid, after being told by others not to pursue it, saw his tumor markers normalize and lived two active, cancer-free years. ➡️ Merkel Cell Carcinoma & Head/Neck Cancer: Stories of complete responses in patients given weeks to live, with one living nine years and another saved from hospice when his ulcerating tumor melted away. Dr. Soon-Shiong is reframing the conversation. This isn't a "vaccine" in the traditional sense. It's Project BioShield—a proactive, cellular guardian for the body. The takeaway? We are transitioning from toxic, reactive cancer therapies to intelligent, preemptive protection. The age of the immune system as our most powerful shield against cancer has arrived. What are your thoughts on this "BioShield" approach to cancer?

Camus

31,256 просмотров • 9 месяцев назад

Ivermectin & Fenbendazole Cancer Secrets Revealed w/ Dr. William Makis Remarkable success stories are pouring in from people using Ivermectin and Fenbendazole to combat cancer. Mel Gibson dropped a bombshell on Joe Rogan’s podcast, revealing that three of his friends had “stage four cancer,” and now “all three of them don’t have cancer right now at all.” “And they had some serious stuff going on,” Gibson emphasized. Dr. William Makis, who treated one of Gibson’s friends, has been rigorously researching the anti-cancer potential of Ivermectin and Fenbendazole over the past two years. During that time, he discovered, “There are over 100 papers on the success of Ivermectin and cancer.” “Ivermectin can actually kill cancer stem cells,” Dr. Makis explained, noting that it targets the cells “that chemo can’t kill.” He added, “It can also reverse resistance that cancer cells develop to certain types of chemotherapy.” The benefits extend further. “It [Ivermectin] makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer,” he shared. Yet, research into these applications has been neglected. “Big Pharma has completely abandoned it. Ivermectin is off-patent. No one’s going to make money on it,” Dr. Makis pointed out. Taking action where others haven’t, Dr. Makis applied his findings to his practice. “I have over 1,000 cancer patients who are on either a combination of Ivermectin and Fenbendazole or Ivermectin and Mebendazole,” he shared. Some of his patients were “given a terminal diagnosis” but are now “cancer-free” or have their “cancer under control.” “Patients, for example, who are taking combinations of chemo and Ivermectin or radiation and Ivermectin are seeing dramatic results that oncologists have never seen, that radiation oncologists have never seen,” Dr. Makis shared. “Tumors shrinking down to almost nothing, liver metastases disappearing, brain metastases disappearing.” “There are hundreds, if not thousands, of testimonials” documenting the success stories of Ivermectin and Fenbendazole, Dr. Makis added, offering hope to patients seeking alternatives. He strongly believes that “the future of cancer care is in repurposed drugs.” For more information on the use of Ivermectin and Fenbendazole for cancer, follow Dr. William Makis (MakisMD) on 𝕏. --> MakisMD (See 9 More Revealing Stories Below)

The Vigilant Fox 🦊

1,292,906 просмотров • 1 год назад

"Biopsies Spread Cancer...Biopsies Are The Kiss Of Death. The Needle Punches A Hole In The Tumor, Dragging Cancer Cells & Spreading Them." Dr Ben Johnson Doctors Finally Admit That The Very Test Being Pushed On Patients Is Causing Cancer To Metastasize All Throughout The Body. The body self-contains a tumor within a fibrin sheath. A needle biopsy breaks the seal of the tumor that kept it contained & allows the pathogenic toxins &/or parasites to be unleashed. When a hornet's nest is poked, it doesn't calm the hive...it angers & scatters. That’s what happens when a needle pierces a tumor. Cancer cells are dragged into new territory, inflammation flares, the immune system gets distracted, and the “nest” gets angrier. Cells are dragged along the needle tract. Local inflammation activates tumor growth. The immune system is suppressed & cancer cells invade tissue, blood & lymph. Biopsies trigger metastasis, inflammation & tumor seeding: "Biopsy of primary tumors resulted in significantly increased incidence & number of lung metastasis."(PMID 25061543) "Biopsies promote intraperitoneal tumor dissemination & progression." (PMID 23258276) "Core needle biopsy of breast tumors increases distant metastases. (PMID 25425969) "Biopsies lead to tumor cell dissemination & seeding of malignant tumors." (PMID 22686607) "Human breast cancer biopsies enhance adjacent cancer cell proliferation." (PMID 27249999) Top Doctors Are Now Admitting 'That Standard Of Care' Is Killing Patients: "Manipulation of an intact tumor...is associated with an increase in the incidence of sentinel node metastasis." (John Wayne Cancer Institute 2022) "Cutting out a section...endangered the person's life by aggravating the malignant growth." (Dr Perry Nichols) "Biopsies spread early cancers." (Dr Jonathan Wright) "Biopsies introduce cancer cells into the bloodstream." (Dr Leonard Gomella) "Biopsies cause cancer cells to spread & the risk is higher in certain types of cancers like prostate & kidney cancers." (Dr Hal Schofield) "Biopsies cause cancer to disseminate further into the body & this has serious implications to patient outcomes." (Dr Robert Nagourney) Alternative Tests That Do Not Disturb Fibrin Sheath Of The Encapsulated Tumor: 1⃣ Multiparametric MRI (pmMRI): Non-invasive. No ionizing radiation. Detects structure & function in high resolution. 2⃣ Color Doppler Ultrasound: Maps tumor blood flow in real time. No radiation. No compression damage. 3⃣ Liquid Biopsy (ctDNA /CTC Testing): Blood test for cancer DNA or cells. No mechanical disruption of tumors. 4⃣ Thermography: Non-radiation, non-invasive technique that uses infrared cameras to detect heat patterns in tumors. Information is anti-fear. Knowledge is power. It gives you choices. It gives you power. If you’ve been diagnosed, please don’t rush. Research. Ask questions. Trust your intuition. Sometimes slowing down is the most urgent thing you can do. The cancer industrial complex is a powerful profit model & needs a massive overhaul. Too many patients blindly walk into these procedures without informed consent, never being told the risks. You can choose to not disturb the tumor at all & instead implement a protocol to shrink & enable the body to eradicate the tumor all together. Many cases of cancer tumors are actually parasitic eggs sacs misdiagnosed as cancer. There are ways to diagnose cancer without the risk of spread & acceleration. And ways to prevent & treat cancer without the harm of Chemotherapy & Radiation. There is a groundbreaking protocol by Dr William Makis, Dr Paul Marik & others that uses Ivermectin, Fenbendazole, Methylene Blue, Fasting, Ketogenic Diet & other proven cancer remission strategies that addresses cancer & parasites simultaneously. ⏩ ⏪ 👇Seeding Tumor Cells Into Metastasis👇 👇Needle Biopsy Promotes Metastasis👇 👇Needle Biopsy Accelerates Cancer👇 Speaker: Justin Stellman

Valerie Anne Smith

771,949 просмотров • 11 месяцев назад

12 science-backed strategies for cancer prevention (00:00) Avoid tobacco — Quitting smoking reduces excess mortality risk by ~90% if done in early adulthood; quitting later can still cut lung cancer risk by 50% within 10–15 years. (00:58) Maintain a healthy body weight — Obesity increases risk for ~13 cancer types. For example, obesity is linked to 50–60% of endometrial cancers. ~11% of cancers in women and ~5% of cancers in men are linked to excess body weight. (02:45) Regular physical activity — At least 150 min/week of vigorous or 300 min/week of moderate exercise significantly reduces cancer risk. (03:32) Eat fiber-rich foods — Each additional 10 grams/day of fiber reduces colorectal cancer risk by ~10%. Eating five servings of fruits and vegetables daily can slash colon cancer risk by 50–60%. (05:46) Limit processed meat and ultra-processed foods — Regular consumption is strongly linked to increased colorectal cancer rates, mirroring the exponential rise in incidence since the 1930s due to dietary shifts. (07:00) Reduce alcohol intake — Daily alcohol consumption significantly raises cancer risk. Even moderate drinking (one drink/day) raises breast cancer risk by ~10%; two to three drinks/day boosts it ~20%. (08:12) Use sunscreen — Consistent sunscreen use reduced melanoma incidence by 50% in a 10-year randomized trial; critical since melanoma rapidly metastasizes. (09:06) Test your home for radon — Radon is the second leading cause of lung cancer in the U.S. Radon enters homes invisibly through soil, particularly during winter when doors and windows stay closed. (09:52) Manage stress — Chronic stress increases cancer incidence through immune and inflammatory pathways, though exact biological mechanisms remain unclear. (10:17) Prioritize sleep and circadian rhythm — Night-shift work is classified as a probable carcinogen due to circadian disruption. Regularly getting 7–8 hours of sleep supports hormonal and immune regulation to reduce cancer risk. (10:56) Vitamin D supplementation — Clinical trials show 2,000 IU/day can reduce cancer-related deaths. Genetic studies reinforce that low vitamin D levels significantly elevate cancer mortality risk. (14:54) Avoid beta-carotene supplements if you previously smoked — High-dose beta-carotene supplements (30 mg/day) increased lung cancer risk by 28% in former smokers, likely due to interactions within lung tissue.

FoundMyFitness Clips

45,633 просмотров • 1 год назад

Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. But the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin has multiple anti-cancer effects. “There are at least nine perfectly defined cancer targets affected by ivermectin,” oncologist Dr. Alfonso Dueñas-González, told The Epoch Times. The news outlet reported: "It [ivermectin] has a broad impact on the immune system, increasing immune offense against cancers." "It also inhibits cancer cell cycles, helping prevent the formation of new cancer cells. The drug promotes the killing of cancer cells by inducing mitochondrial stress and prevents cancer survival by preventing new blood vessels, which transport energy and fuel to cancers, from forming near cancer cells." Dr. Kathleen Ruddy, a cancer surgeon, observed a resounding improvement in three patients under her consultation after they started using ivermectin with additional therapies. One patient, facing terminal stage 4 prostate cancer and given only three weeks to live after all treatments failed, began using ivermectin. Remarkably, within two months, his indicators of prostate cancer plummeted, and by six months, his cancer had significantly receded. Less than a year later, he was energetically dancing for four hours, three nights a week. This miraculous recovery was not isolated, as two more patients experienced similar outcomes. Dr. Ruddy, with over 30 years in cancer surgery, reflected on these cases, saying, “I’ve been a cancer surgeon for over 30 years. I’ve never seen anything like this in one patient—let alone three in a row.” Read the full report in the comment below:

The Vigilant Fox 🦊

1,192,363 просмотров • 2 лет назад

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

422,251 просмотров • 10 месяцев назад

Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."

Sense Receptor

96,616 просмотров • 9 месяцев назад

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

MJTruthUltra

29,659 просмотров • 22 дней назад

Fenbendazole & Cancer Remission: The Peer-Reviewed Cases Challenging Modern Oncology A peer-reviewed medical publication has delivered a bombshell that the mainstream oncology world cannot ignore. It documents three cases of patients with advanced, metastatic cancer who achieved remarkable remissions after a radical course of action: self-medicating with veterinary-grade medication. The paper details three individuals who were essentially out of conventional options: ➡️ Case 1: An 83-year-old woman with stage 4 breast cancer that had spread to her liver, lungs, and bones. After refusing chemotherapy and entering hospice care, she began a regimen of fenbendazole (a dewormer for dogs), Vitamin D, and multivitamins. By June 2022, her cancer was in complete remission. She has been cancer-free for over three years. ➡️ Case 2: A man with stage 4 prostate cancer and extensive bone metastases. While on standard hormone therapy, he added high-dose fenbendazole and a cocktail of supplements (Vitamin K2, magnesium, melatonin, curcumin). The result? Within 26 months, his cancer growth and spread had completely halted. ➡️ Case 3: A man in his 60s with advanced melanoma, slated for immunotherapy. While waiting for treatment, he began the same fenbendazole and vitamin protocol. By February 2024, before even starting the planned drug, his cancer had completely disappeared. The Critical Nuance Everyone Must Understand: The authors of this paper are NOT advocating for patients to self-medicate with veterinary drugs. The purpose of publishing these cases is precisely the opposite: to sound an alarm. When patients in desperate situations feel compelled to turn to clandestine, unapproved treatments, it is a clear sign that current options are failing them. This paper uses these dramatic "success stories" as a powerful call to action for the scientific community to launch proper clinical trials. The central question is no longer just if cancer metabolism can be targeted, but how we can safely and effectively harness these pathways. The combination of a repurposed drug with foundational lifestyle and nutritional support (the common denominator in all three cases) presents a compelling, albeit unorthodox, avenue for research. This is where the conversation about medical freedom, patient desperation, and scientific rigor collides. It underscores an urgent need to explore all promising pathways, especially those that are patient-driven, with the rigor they deserve. What are your thoughts on the role of repurposed drugs in modern oncology?

Camus

50,547 просмотров • 9 месяцев назад

Dr. Patrick Soon-Shiong presents a fundamental paradigm shift in the war on cancer: we must stop destroying the immune system to save the body, and start supercharging it to achieve a permanent cure. The critical flaw of conventional chemotherapy and radiation is their inadvertent destruction of the very immune cells—the lymphocytes—designed to protect us. This often wins a battle but loses the war, leading to metastasis. The solution lies within us. Dr. Soon-Shiong’s work harnesses "God's design": the power of Natural Killer (NK) cells and T-cells. The breakthrough is two-fold: 1. The Activation Key: For the first time, we can effectively activate these cells using a sustained-release form of IL-15, a natural protein. A single injection can create a tenfold increase in the body's innate cancer-killing army. 2. The Army Expansion: We can now draw a patient's blood, grow billions of targeted NK cells in a lab, and reinfuse them, creating a supercharged, augmented immune response. This is not an incremental improvement. It is a move away from the failed strategy of attacking cancer from the inside-out—blocking internal pathways that cancer easily bypasses—to shattering it from the outside-in. The result is data that speaks to a potential cure: patients with metastatic pancreatic cancer alive and disease-free after five years; bladder cancer patients thriving with their organs intact a decade after treatment; long-term remission in aggressive Merkel cell carcinoma. This approach teaches the immune system "T-cell memory," creating a permanent, living surveillance system that stands guard against recurrence. This is the path to long-term survival with quality of life.

Camus

103,022 просмотров • 11 месяцев назад

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 просмотров • 2 месяцев назад